Compare IDEXX Laboratories, Inc. (IDXX) vs D Wave Quantum Inc (QBTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs D Wave Quantum Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while D Wave Quantum Inc trades at $14.57 (market cap $5.54B). The key difference: IDEXX Laboratories, Inc. is far larger — about 7.3× D Wave Quantum Inc's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 16,671,452). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and D Wave Quantum Inc for 32 Days on average.
| IDXX | QBTS | |
|---|---|---|
Market Cap | $40.43B | $5.54B |
Volume | 692,164 | 16,671,452 |
Sector | Health | Technology |
52-Week High | $766.68 | $44.78 |
52-Week Low | $504.70 | $12.98 |
Typical Hold Time | 46 Days | 32 Days |
Enterprise Value | $41.32B | $5.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
D-Wave Quantum (QBTS) trades at $14.60, down 4.07% with a bearish technical signal despite unanimous analyst buy ratings and a $34.38 consensus target. The quantum computing company shows concerning fundamentals with a P/S ratio of 421.36 and negative profitability metrics, including a -2,001.59% net income margin. Recent quarterly earnings have been mixed, missing expectations in Q4 2025 and Q2 2026 while beating in Q1 2026.
While analyst optimism remains high with 100% buy ratings, significant financial risks persist including ongoing losses, negative cash flow projections for 2026, and multiple fraud investigations. The stock faces substantial execution risk in the competitive quantum computing space, though long-term potential exists if the company can achieve commercial scalability and positive cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →
